国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2012年
4期
535-539
,共5页
大肠埃希菌%肺炎克雷伯菌%产超广谱β-内酰胺酶%耐药性
大腸埃希菌%肺炎剋雷伯菌%產超廣譜β-內酰胺酶%耐藥性
대장애희균%폐염극뢰백균%산초엄보β-내선알매%내약성
Escherichia coli%Klebsiella pneumoniae%Extended spectrum B-lactamase%Drug resistance
目的 监测并分析我院2008-2010年间临床分离的大肠埃希菌和肺炎克雷伯菌产超广谱β-内酰胺酶(ESBLs)的情况及耐药性变化,为临床合理使用抗菌药物提供依据.方法 对分离的大肠埃希菌和肺炎克雷伯菌采用VITEK 2 CMPACT的AST-13卡与K-B纸片扩散法相结合进行药敏试验,用筛选和确证试验确认产ESBLs菌株,用WHONETS.3软件进行数据分析.结果 分离的2132株大肠埃希菌中,产ESBLs的有993株,占46.56％; 1041株肺炎克雷伯菌中,产ESBLs的有438株,占41.98％.产ESBLs菌株的耐药性显著高于非产ESBLs菌株(P＜0.05),产ESBLs菌株呈多重耐药.结论三年来产ESBLs菌的检出率与耐药率呈总体平稳趋势,在抗感染治疗过程中,临床应根据药敏结果合理选择抗菌药物,特别是加强对产ESBLs菌株及其耐药性监测,以减缓细菌耐药性的产生.
目的 鑑測併分析我院2008-2010年間臨床分離的大腸埃希菌和肺炎剋雷伯菌產超廣譜β-內酰胺酶(ESBLs)的情況及耐藥性變化,為臨床閤理使用抗菌藥物提供依據.方法 對分離的大腸埃希菌和肺炎剋雷伯菌採用VITEK 2 CMPACT的AST-13卡與K-B紙片擴散法相結閤進行藥敏試驗,用篩選和確證試驗確認產ESBLs菌株,用WHONETS.3軟件進行數據分析.結果 分離的2132株大腸埃希菌中,產ESBLs的有993株,佔46.56％; 1041株肺炎剋雷伯菌中,產ESBLs的有438株,佔41.98％.產ESBLs菌株的耐藥性顯著高于非產ESBLs菌株(P＜0.05),產ESBLs菌株呈多重耐藥.結論三年來產ESBLs菌的檢齣率與耐藥率呈總體平穩趨勢,在抗感染治療過程中,臨床應根據藥敏結果閤理選擇抗菌藥物,特彆是加彊對產ESBLs菌株及其耐藥性鑑測,以減緩細菌耐藥性的產生.
목적 감측병분석아원2008-2010년간림상분리적대장애희균화폐염극뢰백균산초엄보β-내선알매(ESBLs)적정황급내약성변화,위림상합리사용항균약물제공의거.방법 대분리적대장애희균화폐염극뢰백균채용VITEK 2 CMPACT적AST-13잡여K-B지편확산법상결합진행약민시험,용사선화학증시험학인산ESBLs균주,용WHONETS.3연건진행수거분석.결과 분리적2132주대장애희균중,산ESBLs적유993주,점46.56％; 1041주폐염극뢰백균중,산ESBLs적유438주,점41.98％.산ESBLs균주적내약성현저고우비산ESBLs균주(P＜0.05),산ESBLs균주정다중내약.결론삼년래산ESBLs균적검출솔여내약솔정총체평은추세,재항감염치료과정중,림상응근거약민결과합리선택항균약물,특별시가강대산ESBLs균주급기내약성감측,이감완세균내약성적산생.
Objective To monitor and analyze the circumstances of clinical isolates of Escherichia coli and Klebsiella pneumoniae producing ESBLs and the change of drug resistance between 2008 to 2010,to provide the evidence for clinical rational use of antimicrobial.Methods The susceptibility of the isolates of Escherichia coli and Klebsiella pneumoniae was detected by AST-13 of VITEK 2 CMPACT combined with K-B disk diffusion,the ESBLs-producing strains were confirmed by screening and confirmatory tests,software WHONET 5.3 was used for data analysis.Results In 2132 strains of Escherichia coli,993(46.56％) ESBLs-producing strains were 438(41.98％) confirmed.ESBLs-producing strains were confirmed out of 1041 Klebsiella pneumoniae strains.Drug resistance of the strains producing ESBLs was significantly higher than that of the non-producing ESBLs strains (P ＜ 0.05),ESBLs-producing strains were muti-drug resistant strains.Conclusion Detection rate and drug resistance of the strains producing ESBLs was appeared stable tendency.In anti-infection treatment process,the clinical should choose the antimicrobial reasonably based on the susceptibility results,especially strengthen the monitoring of ESBLs-producing strains and drug resistance,in order to reduce bacterial drug resistance.
